A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: The Nordic ACT2 trial

Annals of Oncology

Volumn 27, Issue 1, 2016, Pages 140-147

  Hagman, Helga ^a   Frodin J E ^b   Berglund, A ^c   Sundberg, J ^d   Vestermark, L W ^e   Albertsson, M ^f   Fernebro, E ^g   Johnsson, A ^d  

^a RYHOV COUNTY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g Vaxjo Hospital   (Sweden)

Author keywords

Bevacizumab; Capecitabine; Erlotinib; Maintenance treatment; Metastatic colorectal cancer; Metronomic chemotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; APPETITE DISORDER; ARTICLE; ASTHENIA; COHORT ANALYSIS; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINESTINAL STENOSIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL STENOSIS; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; HYPOKALEMIA; INFECTION; KIDNEY DISEASE; LIVER DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SUBCUTANEOUS TISSUE DISORDER; THROMBOSIS; URETER OBSTRUCTION; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; INDUCTION CHEMOTHERAPY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MAINTENANCE CHEMOTHERAPY; METRONOMIC DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, METRONOMIC; ADULT; AGED; AGED, 80 AND OVER; BEVACIZUMAB; CAPECITABINE; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 84960127748     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv490     Document Type: Article

References (14)

1. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl 3): iii1-iii9.
2. Sun JF, Wu RR, Norris C et al. Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers. Gastrointest Cancer Res 2009; 3: 134-140.
3. Johnsson A, Hagman H, Frodin JE et al. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. Ann Oncol 2013; 24: 2335-2341.
4. Koeberle D, Betticher DC, von Moos R et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/ 06). Ann Oncol 2015; 26: 709-714.
5. Simkens LH, van Tinteren H, May A et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385: 1843-1852.
6. Hegewisch-Becker S, Graeven U, Lerchenmuller CA et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2015; 16: 1355-1369.
7. Johnson BE, Kabbinavar F, Fehrenbacher L et al. ATLAS: randomized, doubleblind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2013; 31: 3926-3934.
8. Munoz A, Pericay C, Garcia-Giron C et al. Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. Oncol Res 2013; 21: 181-191.
9. Chibaudel B. Bevacizumab-erlotinib as maintenance therapy in metastatic colorectal cancer. Final results of the GERCOR DREAM study. Ann Oncol 2014 (ESMO Congress abstract 497O).
10. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
11. Linardou H, Dahabreh IJ, Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-972.
12. Tournigand C. Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: results of the GERCOR DREAM phase III. J Clin Oncol 2013; 31(suppl): abstr 3515.
13. Kabbinavar F, Fehrenbacher L, Hainsworth J et al. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-smallcell lung cancer (ATLAS). J Thorac Oncol 2014; 9: 1411-1417.
14. Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18: 1337-1345.